Cadre (CDRE) vs TriMas (TRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TriMas (TRS) has outperformed Cadre (CDRE) over the past year, gaining 14.5% versus a loss of 26.8%. Over five years, CDRE leads with a +51.0% price change compared with +4.4% for TRS. TriMas is the larger company by market cap ($1.30 billion vs $1.26 billion), about 1.0 times the size, while Cadre is growing revenue faster (+7.5% vs +2.4%).
On valuation, TriMas trades at a lower forward P/E (17.7x vs 18.5x for Cadre). Cadre offers the higher dividend yield (1.34% vs 0.44%). TriMas converts more of its revenue into profit, with a net margin of 18.6% versus 7.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDRE | TRS |
|---|---|---|
| Share price | $29.45 | $36.77 |
| Market cap | $1.26B | $1.30B |
| 1-day change | -3.63% | -2.52% |
| YTD return | -27.89% | +3.72% |
| 1-year return | -26.83% | +14.48% |
| 5-year return | +51.03% | +4.43% |
| P/E ratio (TTM) | 32.36 | 14.42 |
| Forward P/E | 18.53 | 17.75 |
| EPS (TTM) | $0.91 | $2.55 |
| Dividend yield | 1.34% | 0.44% |
| Annual dividend | $0.395 | $0.16 |
| Revenue (latest FY) | $610.31M | $645.72M |
| Revenue growth (YoY) | +7.53% | +2.37% |
| Net income (latest FY) | $44.14M | $120.14M |
| Gross margin | 42.54% | 21.40% |
| Operating margin | 11.04% | 6.40% |
| Net margin | 7.23% | 18.61% |
| 52-week high | $48.76 | $45.43 |
| 52-week low | $24.07 | $31.67 |
| Distance from 52-week high | -39.60% | -19.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +59.02% | +22.38% |
| Average volume | 464.00K | 376.88K |
| Shares outstanding | 42.92M | 35.29M |
| Employees | 2,533 | 2,500 |
| Sector | Health Care | Industrials |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRS has outperformed CDRE by 41.3 percentage points over the past year.
- Cadre trades at a higher earnings multiple (32.4x vs 14.4x trailing P/E).
- TriMas is more profitable, keeping 18.6 cents of every revenue dollar as net income versus 7.2 cents for Cadre.
- Cadre grew revenue faster in its latest fiscal year (+7.53% vs +2.37%).
- The two companies sit in different sectors: Cadre in Health Care and TriMas in Industrials.
About Cadre
CDRE stock →Cadre Holdings, Inc. manufactures and distributes safety equipment and other related products that provides protection to users in hazardous or life-threatening situations in the United States and internationally.
Health Care · Industrial Specialties · 2,533 employees
About TriMas
TRS stock →TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace and defense, and industrial markets worldwide. The company operates through Packaging and Specialty Products segments.
Industrials · Industrial Specialties · 2,500 employees
CDRE vs TRS FAQ
Which is bigger, Cadre or TriMas?
TriMas (TRS) is larger, with a market capitalization of $1.30B compared with $1.26B for Cadre (CDRE).
Which stock has performed better over the past year, CDRE or TRS?
TRS returned +14.48% over the past 12 months, compared with -26.83% for CDRE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CDRE or TRS?
TRS has the lower trailing P/E at 14.4, versus 32.4 for CDRE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Cadre or TriMas?
Cadre has the higher yield at 1.34%, compared with 0.44% for TriMas.
Are Cadre and TriMas in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.